HYHitomi Yuki

Hitomi Yuki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hitomi Yuki has a total of 229 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    GTP hydrolysis by Ras proceeds without a stabilized nucleophilic water molecule

    by Takashi Kawamura, Wakako Fujimoto-Sakisaka, Yoshiteru Makino, Shigeyuki Matsumoto, Tatsuya Ohyama, Yoko Yoshikawa, Chiduru Watanabe, Fangjia Luo, Taisuke Horikawa, Yuto Nagoshi, et al.

    A comprehensive understanding of the Ras self-inactivation mechanism at atomic resolution-specifically, intrinsic GTP hydrolysis converting the GTP-bound active form to the GDP-bound inactive form-is essential for designing therapies against Ras-driven cancers. Conventional models describe a biphasic GTP-bound state: Ras interconverts between inactive state 1 and active, catalytically competent state 2. However, the structural pathway leading to Ras/GDP via these states remains unclear. Here, we use time-resolved serial femtosecond and synchrotron crystallography to capture GTP hydrolysis in Ras crystals loaded with photoactivatable caged GTP, across timescales from milliseconds to hours. Photolysis yielded Ras in state 1-a conformation lacking a stabilized nucleophilic water characteristic of state 2. Remarkably, this state persists for hours and converts directly to Ras/GDP without passing through state 2. These findings challenge the prevailing view that state 2 is essential and suggest that state 1 can directly support catalysis, offering an alternative conceptual basis for targeting clinically relevant Ras mutants that preferentially adopt this conformation.

  • Open Access

    Small-molecule RAS/RAF inhibitors target RAS-driven cancers via allosteric RAF disruption

    by Yoko Yoshikawa, Hirokazu Kubota, Shigeyuki Matsumoto, Yoshiteru Makino, Takashi Kawamura, Hitomi Yuki, Naoki Sakai, Akira Shibaike, Megumi Okamura, Wakako Fujimoto-Sakisaka, et al.

  • Open Access

    Data-Driven Design of PROTAC Linkers to Improve PROTAC Cell Membrane Permeability

    by Yuki Murakami, Shoichi Ishida, Nobuo Cho, Hitomi Yuki, Masateru Ohta, Teruki Honma, Yosuke Demizu, Kei Terayama

    Proteolysis-targeting chimeras (PROTACs) are promising next-generation therapeutics for the degradation of disease-associated proteins. However, optimizing the physicochemical properties of PROTACs, particularly their poor cell membrane permeability, remains challenging. Traditionally, PROTAC linkers have been manually designed to improve cell membrane permeability. Although recent machine learning-based approaches have enabled the rational design of PROTAC linkers, no linker design methods that explicitly address cell membrane permeability have been reported. In this study, we developed PROTAC-TS, a linker generative model that combines a chemical language model and reinforcement learning to control cell membrane permeability. We first constructed a prediction model of cell membrane permeability, which achieved high prediction performance (R 2 = 0.710). By integrating this prediction model into the generative model, we successfully designed linkers of PROTACs with high predicted cell membrane permeability while considering PROTAC likeness. Our results highlight the potential of PROTAC-TS in accelerating PROTAC development with favorable cell membrane permeability.


  • Open Access

    Data-driven Design of PROTAC Linkers to Improve PROTAC Cell Membrane Permeability

    by Yuki Murakami, Shoichi Ishida, Nobuo Cho, Hitomi Yuki, Masateru Ohta, Teruki Honma, Yosuke Demizu, Kei Terayama

    Proteolysis-targeting chimeras (PROTACs) are promising next-generation therapeutics for the degradation of disease-associated proteins. However, optimizing the physicochemical properties of PROTACs, particularly their poor cell mem-brane permeability, remains challenging. Traditionally, PROTAC linkers have been manually designed to improve cell membrane permeability. Although recent machine learning-based approaches have enabled the rational design of PROTAC linkers, no linker design methods that explicitly address cell membrane permeability have been reported. In this study, we developed PROTAC-TS, a linker generative model that combines a chemical language model and reinforcement learning to control cell membrane permeability. We first constructed a prediction model of cell membrane permeability, which achieved high prediction performance (R2 = 0.710). By integrating this prediction model into the generative model, we successfully designed linkers of PROTACs with high predicted cell membrane permeability while considering PROTAC likeness. Our results highlight the potential of PROTAC-TS in accelerating PROTAC development with favorable cell membrane permea-bility.


  • Open Access

    Small-molecule RAS/RAF Binding Inhibitors Allosterically Disrupt RAF Conformation and Exert Efficacy Against a Broad Spectrum of RAS-driven Cancers

    by Fumi Shima, Yoko Yoshikawa, Yoshiteru Makino, Hirokazu Kubota, Takashi Kawamura, Shigeyuki Matsumoto, Hitomi Yuki, Akira Shibaike, Megumi Okamura, Tomoyo Okada, et al.

    With the advent of approved subtype-specific RAS inhibitors targeting KRASG12C mutation, the development of RAS inhibitors effective regardless of RAS mutation status is the next major challenge to address clinically prevalent RAS mutations and further overcome RAS-driven acquired resistance to currently available drugs. Here our multi-module drug screening for compounds capable of RAS/RAF-binding inhibition, and subsequent structural study discovered small-molecule compounds which covalently bind to a unique site in the regulatory domain of RAF, and disrupt RAF conformation allosterically, thereby preventing RAS/RAF-interaction and downstream signals. The compounds exhibit anti-tumor efficacy to multiple cancer types with broad-spectrum RAS mutations including clinically predominant G12D and G12V KRAS, NRAS and HRAS in pre-clinical models. Furthermore, the compounds effectively suppress tumor growth of BRAFV600E-melanoma with acquired resistance to RAF kinase inhibitor. Collectively, our study provides effectiveness for designing RAF-targeting drugs, and potentially therapeutic RAS/RAF-signaling inhibitors with novel mechanism to overcome broad-range RAS-driven cancers.

  • Quantum Chemical Interaction Analysis between SARS-CoV-2 Main Protease and Ensitrelvir Compared with Its Initial Screening Hit

    by Chiduru Watanabe, Shigenori Tanaka, Yoshio Okiyama, Hitomi Yuki, Tatsuya Ohyama, Kikuko Kamisaka, Daisuke Takaya, Kaori Fukuzawa, Teruki Honma


  • Open Access

    Author Correction: Identifying antibiotics based on structural differences in the conserved allostery from mitochondrial heme-copper oxidases

    by Yuya Nishida, Sachiko Yanagisawa, Rikuri Morita, Hideki Shigematsu, Kyoko Shinzawa-Itoh, Hitomi Yuki, Satoshi Ogasawara, Ken Shimuta, Takashi Iwamoto, Chisa Nakabayashi, et al.

  • Open Access

    Identifying antibiotics based on structural differences in the conserved allostery from mitochondrial heme-copper oxidases

    by Yuya Nishida, Sachiko Yanagisawa, Rikuri Morita, Hideki Shigematsu, Kyoko Shinzawa-Itoh, Hitomi Yuki, Satoshi Ogasawara, Ken Shimuta, Takashi Iwamoto, Chisa Nakabayashi, et al.

    Antimicrobial resistance (AMR) is a global health problem. Despite the enormous efforts made in the last decade, threats from some species, including drug-resistant Neisseria gonorrhoeae, continue to rise and would become untreatable. The development of antibiotics with a different mechanism of action is seriously required. Here, we identified an allosteric inhibitory site buried inside eukaryotic mitochondrial heme-copper oxidases (HCOs), the essential respiratory enzymes for life. The steric conformation around the binding pocket of HCOs is highly conserved among bacteria and eukaryotes, yet the latter has an extra helix. This structural difference in the conserved allostery enabled us to rationally identify bacterial HCO-specific inhibitors: an antibiotic compound against ceftriaxone-resistant Neisseria gonorrhoeae. Molecular dynamics combined with resonance Raman spectroscopy and stopped-flow spectroscopy revealed an allosteric obstruction in the substrate accessing channel as a mechanism of inhibition. Our approach opens fresh avenues in modulating protein functions and broadens our options to overcome AMR.


  • Combined inhibition of XIAP and BCL2 drives maximal therapeutic efficacy in genetically diverse aggressive acute myeloid leukemia

    by Mari Hashimoto, Yoriko Saito, Ryo Nakagawa, Ikuko Ogahara, Shinsuke Takagi, Sadaaki Takata, Hanae Amitani, Mikiko Endo, Hitomi Yuki, Jordan A. Ramilowski, et al.

    Aggressive therapy-resistant and refractory acute myeloid leukemia (AML) has an extremely poor outcome. By analyzing a large number of genetically complex and diverse, primary high-risk poor-outcome human AML samples, we identified specific pathways of therapeutic vulnerability. Through drug screens followed by extensive in vivo validation and genomic analyses, we found inhibition of cytosolic and mitochondrial anti-apoptotic proteins XIAP, BCL2 and MCL1, and a key regulator of mitosis, AURKB, as a vulnerability hub based on patient-specific genetic aberrations and transcriptional signatures. Combinatorial therapeutic inhibition of XIAP with an additional patient-specific vulnerability eliminated established AML in vivo in patient-derived xenografts (PDXs) bearing diverse genetic aberrations, with no signs of recurrence during off-treatment follow-up. By integrating genomic profiling and drug-sensitivity testing, this work provides a platform for a precision-medicine approach for treating aggressive AML with high unmet need.


  • Open Access

    The ubiquinone synthesis pathway is a promising drug target for Chagas disease

    by Takeshi Nara, Yukari Nakagawa, Keiko Tsuganezawa, Hitomi Yuki, Katsuhiko Sekimata, Hiroo Koyama, Naoko Ogawa, Teruki Honma, Mikako Shirouzu, Takehiro Fukami, et al.

    Chagas disease is caused by infection with the protozoan parasite Trypanosoma cruzi (T. cruzi). It was originally a Latin American endemic health problem, but now is expanding worldwide as a result of increasing migration. The currently available drugs for Chagas disease, benznidazole and nifurtimox, provoke severe adverse effects, and thus the development of new drugs is urgently required. Ubiquinone (UQ) is essential for respiratory chain and redox balance in trypanosomatid protozoans, therefore we aimed to provide evidence that inhibitors of the UQ biosynthesis have trypanocidal activities. In this study, inhibitors of the human COQ7, a key enzyme of the UQ synthesis, were tested for their trypanocidal activities because they were expected to cross-react and inhibit trypanosomal COQ7 due to their genetic homology. We show the trypanocidal activity of a newly found human COQ7 inhibitor, an oxazinoquinoline derivative. The structurally similar compounds were selected from the commercially available compounds by 2D and 3D ligand-based similarity searches. Among 38 compounds selected, 12 compounds with the oxazinoquinoline structure inhibited significantly the growth of epimastigotes of T. cruzi. The most effective 3 compounds also showed the significant antitrypanosomal activity against the mammalian stage of T. cruzi at lower concentrations than benznidazole, a commonly used drug today. We found that epimastigotes treated with the inhibitor contained reduced levels of UQ9. Further, the growth of epimastigotes treated with the inhibitors was partially rescued by UQ10 supplementation to the culture medium. These results suggest that the antitrypanosomal mechanism of the oxazinoquinoline derivatives results from inhibition of the trypanosomal UQ synthesis leading to a shortage of the UQ pool. Our data indicate that the UQ synthesis pathway of T. cruzi is a promising drug target for Chagas disease.